Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

NCT03707457 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Funding/material support withdrawn

Conditions

Glioblastoma
Glioblastoma Multiforme

Interventions

DRUG: Nivolumab
DRUG: Anti-GITR Monoclonal Antibody MK-4166
DRUG: IDO1 inhibitor INCB024360
DRUG: Ipilimumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]